The hepatitis C protease inhibitor simeprevir received marketing approval in the European Union in May 2014. Simeprevir will be marketed under the brand name Olysio. Simeprevir is a second-generation protease inhibitor that is approved for use in combination with other agents for treatment of hepatitis C genotype 1 or 4.
Simeprevir is licensed for use in combination with sofosbuvir (with or without ribavirin) in a 12-week treatment course for genotypes 1 or 4, for people who urgently need treatment and are either ineligible for interferon or intolerant.
Simeprevir is also licensed for use in combination with pegylated interferon and ribavirin (12 weeks of triple therapy followed by 12 weeks of pegylated interferon and ribavirin, or 36 weeks in previous non-responders) for genotypes 1 or 4.
Connect with infohep on Facebook: Keep up to date with all the latest news and developments.
Follow infohep on Twitter for links to news stories and updates from infohep.org. Follow us at www.twitter.com/infohep.
Follow all the infohep news by subscribing to our RSS feeds.